⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378229 | 0.86 | HRH4 (0.31) | — | |
| SCHEMBL7961327 | 0.75 | RAB9A (0.43) | — | |
| SCHEMBL4562590 | 0.72 | — | — | |
| SCHEMBL7972615 | 0.71 | HRH3 (0.37) | — | |
| SCHEMBL9119601 | 0.70 | CYP19A1 (0.54) | — | |
| SCHEMBL1319549 | 0.69 | MAPK1 (0.56) | — | |
| SCHEMBL9728051 | 0.69 | CYP19A1 (0.51) | — | |
| SCHEMBL5322896 | 0.69 | HRH4 (0.32) | — | |
| SCHEMBL10819616 | 0.69 | HRH3 (0.35) | — | |
| SCHEMBL7977252 | 0.69 | NOS1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006120-A1 | Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity | YATES STEPHEN L (US) | 2004-01-08 | — | — | US | claimed |
| EP-1320364-A1 | THE USE OF HISTAMINE H3-RECEPTOR INVERSE AGONISTS FOR THE CONTROL OF APPETITE AND TREATMENT OF OBESITY | GLIATECH, INC. (US) | 2003-06-25 | — | — | EP | claimed |
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | GLIATECH, INC. | 2003-04-10 | — | — | US | claimed |
| WO-2002015905-A1 | THE USE OF HISTAMINE H3 RECEPTOR INVERSE AGONISTS FOR THE CONTROL OF APPETITE AND TREATMENT OF OBESITY | GLIATECH, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| US-20080242657-A1 | Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-02 | — | — | US | disclosed |
| EP-1816912-A4 | TREATMENT OF STROKE WITH HISTAMINE H3 INVERSE AGONISTS OR HISTAMINE H3 ANTAGONISTS | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20080139614-A1 | Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists | MERCK & CO., INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1816912-A2 | TREATMENT OF STROKE WITH HISTAMINE H3 INVERSE AGONISTS OR HISTAMINE H3 ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1732544-A2 | TREATMENT OF TREMOR WITH HISTAMINE H3 INVERSE AGONISTS OR HISTAMINE H3 ANTAGONISTS | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006058023-A2 | TREATMENT OF STROKE WITH HISTAMINE H3 INVERSE AGONISTS OR HISTAMINE H3 ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005097111-A2 | TREATMENT OF TREMOR WITH HISTAMINE H3 INVERSE AGONISTS OR HISTAMINE H3 ANTAGONISTS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20040006120-A1 | Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity | YATES STEPHEN L (US) | 2004-01-08 | — | — | US | disclosed |
| EP-1320364-A1 | THE USE OF HISTAMINE H3-RECEPTOR INVERSE AGONISTS FOR THE CONTROL OF APPETITE AND TREATMENT OF OBESITY | GLIATECH, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030069295-A1 | Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity | GLIATECH, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002015905-A1 | THE USE OF HISTAMINE H3 RECEPTOR INVERSE AGONISTS FOR THE CONTROL OF APPETITE AND TREATMENT OF OBESITY | GLIATECH, INC. (US) | 2002-02-28 | — | — | WO | disclosed |